Literature DB >> 6195201

A comparative trial of three treatment schedules for the eradication of scabies.

D Taplin, A Rivera, J G Walker, W I Roth, D Reno, T Meinking.   

Abstract

A trial of three treatment schedules, consisting of 1% gamma benzene hexachloride (GBH) lotion applied head to toe and left on the body for 2, 6, or 12 to 24 hours was conducted on an island of 2,076 persons, approximately 70% of whom had clinical evidence of scabies. The island is situated off the north coast of the Republic of Panama. Examination at 1 month after therapy showed that both the 6-hour and 12- to 24-hour cure rate was high (96% and 98%). There was a significantly lower cure rate in the 2-hour group, in which only 82% were cured. Eleven to twelve percent of the subjects became infested in all groups, presumably due to contact with untreated persons with scabies on the island. A single 6-hour application of 1% GBH lotion appears to be adequate therapy for scabies if properly applied. The entire population at risk should be treated at the same time if possible to reduce or eliminate the risk of infestation. No adverse reactions to 1% GBH lotion were observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195201     DOI: 10.1016/s0190-9622(83)70168-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Pharmacotherapy of ectoparasitic infections.

Authors:  T C Roos; M Alam; S Roos; H F Merk; D R Bickers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Is the treatment of scabies hazardous?

Authors:  C Wilkinson
Journal:  J R Coll Gen Pract       Date:  1988-10

3.  Man's Closest Companions.

Authors:  R G Mathias; J F Wallace
Journal:  Can Fam Physician       Date:  1987-01       Impact factor: 3.275

Review 4.  Scabies: more than just an irritation.

Authors:  J S McCarthy; D J Kemp; S F Walton; B J Currie
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

Review 5.  A risk-benefit assessment of agents used in the treatment of scabies.

Authors:  M L Elgart
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

6.  Disease burden and health-care clinic attendances for young children in remote aboriginal communities of northern Australia.

Authors:  Danielle B Clucas; Kylie S Carville; Christine Connors; Bart J Currie; Jonathan R Carapetis; Ross M Andrews
Journal:  Bull World Health Organ       Date:  2008-04       Impact factor: 9.408

Review 7.  Interventions for treating scabies.

Authors:  M Strong; P Johnstone
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 8.  Problems in diagnosing scabies, a global disease in human and animal populations.

Authors:  Shelley F Walton; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

9.  Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin.

Authors:  Michael Marks; Lucia Romani; Oliver Sokana; Lazarus Neko; Relmah Harrington; Titus Nasi; Handan Wand; Margot J Whitfeld; Daniel Engelman; Anthony W Solomon; John M Kaldor; Andrew C Steer
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

10.  Scabies and impetigo in Samoa: A school-based clinical and molecular epidemiological study.

Authors:  George Taiaroa; Ben Matalavea; Malama Tafuna'i; Jake A Lacey; David J Price; Lupeoletalalelei Isaia; Hinauri Leaupepe; Satupaitea Viali; Darren Lee; Claire L Gorrie; Deborah A Williamson; Susan Jack
Journal:  Lancet Reg Health West Pac       Date:  2020-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.